Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q4 2018 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Feb 21, 2019
Slide 1: Fourth Quarter 2018 Earnings Call Presentation
Fourth Quarter 2018 Earnings Call Presentation February 21, 2019 NASDAQ: ANIK 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate mi
Slide 3: Foundation for Long-Term Growth
Foundation for Long-Term Growth People Pipeline Profitability 2
Slide 4: CINGAL Update
CINGAL Update Recently met with the U.S. FDA in Q1 2019 Additional Phase III clinical trial required to obtain approval for CINGAL Waiting to receive written meeting minutes; Discussions with FDA ongoing to obtain alignment on approval requirements CINGAL OUS revenue increased 34% for the full year
Slide 5: HYALOFAST Update
HYALOFAST Update Continuing to pursue strategies to accelerate clinical trial enrollment HYALOFAST Phase III trial patient enrollment has advanced past the 50% mark HYALOFAST is an important and innovative product with a high degree of enthusiasm among physicians and patients U.S. market opportunity
Slide 6: Growing Portfolio of Regenerative Treatments
Growing Portfolio of Regenerative Treatments BONE REPAIR THERAPY Commercial launch expected in 2H 2019 Plan to utilize hybrid commercial model Showcasing at multiple upcoming industry conferences U.S. market opportunity of $250-300M annually ROTATOR CUFF REGENERATIVE THERAPY Continued product develo
Slide 7: Q4 & FY 2018 Financial Highlights
Q4 & FY 2018 Financial Highlights Total Revenue Diluted EPS Product Gross Margin (Millions) $35M $0.54 $0.53 74% 70% Operating Cash Flow $29.4 for FY 2018 $27.0 $159M Cash & Investments as of 12/31/2018; No Debt Q4 2018 Q4 2017 Q4 2018 Q4 2017 Q4 2018 Q4 2017 Global MONOVISC revenue grew 12% for the
Slide 8: 2019 Guidance & Key Initiatives
2019 Guidance & Key Initiatives FY 2019 Guidance 2019 Key Initiatives Total revenue is expected to be Launching Anika’s first HA-based, approximately 3%-6% below FY 2018 surgically-delivered regenerative therapy for bone repair procedures Total operating expenses are expected to be in the range of h
Slide 9: Near and Long-Term Growth Drivers
Near and Long-Term Growth Drivers Launch of hybrid commercial model in 2019 International expansion of Orthobiologics franchise - Focused on MONOVISC, CINGAL, & HYALOFAST Continued clinical development of robust product pipeline - Plan to announce new head of R&D team Leveraging financial strength t
Slide 10: Q&A
Q&A Fourth Quarter 2018 Earnings Call Presentation February 21, 2019 NASDAQ: ANIK 9